Genotype-phenotype associations of the CD-associated single nucleotide polymorphism within the gene locus encoding protein tyrosine phosphatase non-receptor type 22 in patients of the Swiss IBD cohort by Spalinger, Marianne R et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Genotype-phenotype associations of the CD-associated single nucleotide
polymorphism within the gene locus encoding protein tyrosine phosphatase
non-receptor type 22 in patients of the Swiss IBD cohort
Spalinger, Marianne R; Zeitz, Jonas; Biedermann, Luc; Rossel, Jean-Benoit; Sulz, Michael C; Frei,
Pascal; Scharl, Sylvie; Vavricka, Stephan R; Fried, Michael; Rogler, Gerhard; Scharl, Michael; Swiss
IBD Cohort Study Group
Abstract: BACKGROUND Protein tyrosine phosphatase non-receptor type 22 (PTPN22) plays an im-
portant role in immune cell function and intestinal homeostasis. The single nucleotide polymorphism
(SNP) rs2476601 within the PTPN22 gene locus results in aberrant function of PTPN22 protein and
protects from Crohn’s disease (CD). Here, we investigated associations of PTPN22 SNP rs2476601 in
inflammatory bowel disease (IBD) patients in the Swiss IBD Cohort Study (SIBDCS). METHODS 2’028
SIBDCS patients (1173 CD and 855 ulcerative colitis (UC) patients) were included. The clinical char-
acteristics were analysed for an association with the presence of the PTPN22 SNP rs2476601 genotypes
’homozygous variant’ (AA), ’heterozygous’ (GA) and ’homozygous wild-type’ (GG). RESULTS 13 pa-
tients (0.6%) were homozygous variant (AA) for the PTPN22 polymorphism, 269 (13.3%) heterozygous
variant (GA) and 1’746 (86.1%) homozygous wild-type (GG). In CD, AA and GA genotypes were associ-
ated with less use of steroids and antibiotics, and reduced prevalence of vitamin D and calcium deficiency.
In UC the AA and GA genotype was associated with increased use of azathioprine and anti-TNF anti-
bodies, but significantly less patients with the PTPN22 variant featured malabsorption syndrome (p =
0.026). CONCLUSION Our study for the first time addressed how presence of SNP rs2476601 within the
PTPN22 gene affects clinical characteristics in IBD-patients. Several factors that correlate with more
severe disease were found to be less common in CD patients carrying the A-allele, pointing towards a
protective role for this variant in affected CD patients. In UC patients however, we found the opposite
trend, suggesting a disease-promoting effect of the A-allele.
DOI: https://doi.org/10.1371/journal.pone.0160215
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-134502
Veröffentlichte Version
 
 
Originally published at:
Spalinger, Marianne R; Zeitz, Jonas; Biedermann, Luc; Rossel, Jean-Benoit; Sulz, Michael C; Frei,
Pascal; Scharl, Sylvie; Vavricka, Stephan R; Fried, Michael; Rogler, Gerhard; Scharl, Michael; Swiss IBD
Cohort Study Group (2016). Genotype-phenotype associations of the CD-associated single nucleotide
polymorphism within the gene locus encoding protein tyrosine phosphatase non-receptor type 22 in
patients of the Swiss IBD cohort. PLoS ONE, 11(7):e0160215.
DOI: https://doi.org/10.1371/journal.pone.0160215
2
RESEARCH ARTICLE
Genotype-Phenotype Associations of the CD-
Associated Single Nucleotide Polymorphism
within the Gene Locus Encoding Protein
Tyrosine Phosphatase Non-Receptor Type 22
in Patients of the Swiss IBD Cohort
Marianne R. Spalinger1☯, Jonas Zeitz1☯, Luc Biedermann1, Jean-Benoit Rossel2, Michael
C. Sulz3, Pascal Frei1, Sylvie Scharl1, Stephan R. Vavricka1,4, Michael Fried1,4,
Gerhard Rogler1,4, Michael Scharl1,4*, Swiss IBD Cohort Study Group¶
1 Division of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich,
Switzerland, 2 Institute of Social and Preventive Medicine, Université de Lausanne, Lausanne, Switzerland,
3 Division of Gastroenterology and Hepatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 4 Zurich
Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
☯ These authors contributed equally to this work.
¶ Membership of the Swiss IBD is listed in the Acknowledgments.
*michael.scharl@usz.ch
Abstract
Background
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) plays an important role in
immune cell function and intestinal homeostasis. The single nucleotide polymorphism
(SNP) rs2476601 within the PTPN22 gene locus results in aberrant function of PTPN22 pro-
tein and protects from Crohn’s disease (CD). Here, we investigated associations of
PTPN22 SNP rs2476601 in inflammatory bowel disease (IBD) patients in the Swiss IBD
Cohort Study (SIBDCS).
Methods
2’028 SIBDCS patients (1173 CD and 855 ulcerative colitis (UC) patients) were included.
The clinical characteristics were analysed for an association with the presence of the
PTPN22 SNP rs2476601 genotypes ‘homozygous variant’ (AA), ‘heterozygous’ (GA) and
‘homozygous wild-type’ (GG).
Results
13 patients (0.6%) were homozygous variant (AA) for the PTPN22 polymorphism, 269
(13.3%) heterozygous variant (GA) and 1’746 (86.1%) homozygous wild-type (GG). In CD,
AA and GA genotypes were associated with less use of steroids and antibiotics, and
reduced prevalence of vitamin D and calcium deficiency. In UC the AA and GA genotype
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was associated with increased use of azathioprine and anti-TNF antibodies, but significantly
less patients with the PTPN22 variant featured malabsorption syndrome (p = 0.026).
Conclusion
Our study for the first time addressed how presence of SNP rs2476601 within the PTPN22
gene affects clinical characteristics in IBD-patients. Several factors that correlate with more
severe disease were found to be less common in CD patients carrying the A-allele, pointing
towards a protective role for this variant in affected CD patients. In UC patients however, we
found the opposite trend, suggesting a disease-promoting effect of the A-allele.
Introduction
A single nucleotide polymorphism (SNP) within the gene locus encoding protein tyrosine
phosphatase non-receptor type 22 (PTPN22; SNP ID rs2476601) has been associated with an
increased risk to develop autoimmune disorders, including rheumatoid arthritis (RA)[1–3],
systemic lupus erythematosus (SLE)[4–6], Graves disease[7], and type-I diabetes (T1D)[7, 8].
Interestingly, genome-wide association studies (GWAS) that addressed genes associated with
inflammatory bowel disease (IBD), revealed that the very same SNP reduces the risk to develop
Crohn’s disease (CD)[9–12]. While there was no association found with ulcerative colitis (UC)
in most of these studies, one of them found a moderate decrease in UC disease risk, which was
attributed to correlation with reduced TNF serum levels[9]. In contrast to classical autoim-
mune or auto-inflammatory disorders, where the adaptive immune system attacks the body’s
own cells/tissues, current hypothesis suggest that IBD is driven by inflammatory reactions
against the harmless commensal microbiota in the intestine[13–15]. It has been suggested that
genetic factors result in a defective innate immune response towards invading intestinal patho-
gens ultimately driving an over-activation of the adaptive arm of the immune system, what
finally causes severe chronic and/or relapsing intestinal inflammation[13, 14, 16–18]. Although
up to date over 200 gene loci have been associated with an altered risk to develop IBD[19], and
for several of them, basic research has provided important mechanistic insight, it is still not
known how presence of these SNPs affects clinical outcome and/or disease characteristics in
IBD patients.
The CD-associated SNP rs2476601 is located in exon 14 of the PTPN22 gene locus and
results in the substitution of arginine 620 with a tryptophan residue in the PTPN22 protein
product (PTPN22-620W). Although initial studies demonstrated that presence of the variant
results in increased in vitro dephosphorylation capacity[20], the PTPN22-620W variant is
nowadays regarded to lead to an altered-function protein, since more recent studies demon-
strated that mice designed to express the murine orthologue of PTPN2-620W, feature
increased T cell receptor signaling and enhanced levels of autoreactive T cells, phenocopying
the findings in PTPN22 deficient animals[21, 22]. Later, these changes in T cell receptor signal-
ing were attributed to altered substrate specificity of the PTPN22-620W variant[23].
PTPN22 is expressed in all immune cells, including B and T lymphocytes as well as myeloid
immune cells such as monocytes, dendritic cells and macrophages[24], but not in non-hemato-
poietic cells such as intestinal epithelial cells or fibroblasts ([24] and own unpublished data). In
T and B cells, PTPN22 activity attenuates antigen receptor signaling[20, 22, 25], ultimately pro-
moting proliferation and aberrant activation of T and B cells[25–27]. The function of PTPN22
in innate immune cells is less studied, although it seems to be importantly involved in intestinal
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homeostasis: we have found that PTPN22 is reduced in intestinal biopsies of IBD patients
when compared to healthy subjects[28]. This reduction was mainly due to decreased expres-
sion of PTPN22 in CD68+ cells of the monocyte/macrophage linage, while its expression in B
and T cells remained unchanged[28]. Loss of PTPN22 in monocytes results in misbalanced
secretion of inflammatory cytokines in response to IFN-γ and the bacterial cell wall product
muramyl dipeptide, characterized by enhanced levels of IL-6 and IL-8, but decreased IL-12 and
IFN-γ [28, 29]. Further, loss of PTPN22 and presence of PTPN22-620W in macrophages favors
generation of pro-inflammatory M1 macrophages[30], and attenuates toll-like receptor (TLR)4
and TLR7 signaling, resulting in decreased Type-I interferon responses[31, 32]. The impor-
tance of PTPN22 in intestinal homeostasis is further demonstrated by the fact that loss of
PTPN22 results in increased dextran sodium sulfate (DSS)-induced acute colitis[30, 31].
Taken together, these data describe an important role for PTPN22 in regulating inflamma-
tory events in the intestine, but up to date, it has not been addressed how presence of the minor
(A) allele influences clinical course or disease characteristics in affected patients. Therefore,
here we aimed to address how SNP rs2476601 in PTPN22 influences clinical parameters in
patients suffering from IBD. Since SNP rs2476601 is differentially associated with IBD than
with classical inflammatory disorders, we believe that this can give important insight to under-
stand why SNP rs2476601 is negatively associated with CD. Further, a better understanding of
the association between IBD risk loci and the complex pathophysiology of IBD might result in
better prediction of the disease course and therefore might have an important impact on treat-
ment decisions.
Using the patient collective of the Swiss IBD Cohort Study (SIBDCS), we investigated,
whether presence of the CD-associated PTPN22 variant, rs2476601 is associated with distinc-
tive disease characteristics in Swiss IBD patients.
Results
Distribution of PTPN22 alleles in the SIBDCS CD and UC patient
cohorts
We analysed a total of 2’028 IBD patients from the SIBDCS, consisting of 1173 (57.8%) CD
and 855 (42.2%) UC patients. Of the entire set of patients, 13 patients (0.6%) featured the AA
genotype of the PTPN22 polymorphism, 269 (13.3%) carried the heterozygous form (GA) and
1’746 (86.1%) the homozygous wild-type (GG).
In the group of 1173 CD patients 1034 (88.2%) carried the homozygous wild-type allele
(GG) of PTPN22, 136 (11.6%) the heterozygous form (GA) and 3 (0.3%) the AA genotype. In
the UC group 712 (83.3%) carried the homozygous wild-type allele (GG), 133 (15.6%) the het-
erozygous form (GA) and 10 (1.2%) the AA genotype. The groups GA and AA were merged
together to compare existence of the A-allele to its non-existence. When comparing the distri-
bution of these genotypes between the CD and UC group, according to a chi-squared test, the
distributions of these genotypes were significantly different (p = 0.002; Table 1).
Table 1. Distribution of genotypes in UC and CD patients.
Number (%) GG GA or AA p-value (chi2)
Diagnosis
Crohn (1173 patients) 1034 (59.22%) 139 (49.29%) 0.002
UC or IC (855 patients)* 712 (40.78%) 143 (50.71%)
*There are 804 UC and 51 IC patients.
doi:10.1371/journal.pone.0160215.t001
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CD patients carrying the A-allele are treated less often with steroids or
antibiotics
Disease course and response to a certain treatment are crucial clinical parameters to determine
further treatment options, and they might be a factor to evaluate overall disease severity (e.g.
anti-TNF antibodies are frequently used in patients refractory to other treatment approaches).
Therefore, we next addressed whether presence of the A-allele was associated with specific
medications and/or response to medication. In the CD group, the distribution of genotypes sig-
nificantly differed between patients with steroid therapy (910 GG / 111 GA or AA) and those
without steroid therapy (124 GG / 28 GA or AA), which was verified using the chi-squared test
(p-value: 0.007; Fig 1A, S1 Table). This was also statistically significant when comparing the
number of follow-ups with a therapy using steroids (p-value 0.034 by a chi-squared test; S1
Table). Also for the use of antibiotics the distribution of genotypes for those patients with anti-
biotic therapy (525 GG / 58 GA or AA) significantly differed from the CD patients not using
antibiotics (509 GG / 81 GA or AA) with a p-value of 0.045 (Fig 1B: S1 Table). When analysing
the use of anti-TNF antibodies, failure or non-response to anti-TNF therapy, non-response to
steroids, use of azathioprine and/or 6-mercaptopurine, as well as use of methotrexate, cyclo-
sporine and/or tacrolimus, no significant difference could be detected between the genotypes
(GG versus GA/AA; Fig 1C+1D and S1 Table).
In UC patients use of anti-TNF antibodies and use of steroids is
enhanced with the AA or GA genotype
In the UC group, the distribution of genotypes for patients with use of anti-TNF therapy (227
GG / 61 GA or AA) significantly differed from the UC patients not using anti-TNF therapy
Fig 1. Use of steroids, antibiotics, anti-TNF treatment, and azathioprine in CD and UC patients
carrying the A-allele in SNP rs2476601. The graphs show percentage of CD (left two bars in each graph)
and UC patients (right two bars in each graph) treated (white area) or not treated (black area) with A: steroids,
B: antibiotics,C: anti-TNF medication, D: or azathioprine.
doi:10.1371/journal.pone.0160215.g001
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(485 GG / 82 GA or AA) with a p-value of 0.013 by a chi-squared test (Fig 1C). The allele distri-
bution in UC patients using azathioprine, but not in those using 6-mercaptopurine, also dif-
fered significantly (411 GG / 96 GA or AA versus 301 GG / 47 GA or AA; p-value 0.037; Fig
1D). This stayed significant when combining the use of azathioprine/6-mercaptopurine (437
GG / 100 GA or AA with AZA/6-MP versus 275 GG / 43 GA or AA without; p-value 0.049; S2
Table). When analysing the failure or non-response to anti-TNF therapy, use of steroids, num-
ber of follow-ups with a therapy of steroids, non-response to steroids, use of antibiotics, as well
as use of methotrexate, cyclosporine and/or tacrolimus showed no significant difference when
comparing genotypes (GG versus GA/AA; Fig 1 and S2 Table).
Presence of the A-allele is not associated with markers predicting
complicated disease course
Since factors associated with a more severe disease course (e.g. IL-10R polymorphisms[33, 34],
NOD2 variants[35, 36]) may also result in an earlier disease onset, we next analysed whether
the age at first diagnosis is different in patients carrying the A-allele (AA and GA genotype)
from those who do not (GG-genotype). In the CD group, median age at diagnosis was 24.6
years (q25-q75: 18.3–34.5; min-max: 0.5–81.4) in the GG group, and 25.4 years (q25-q75:
18.7–36.6; min-max: 6.5–73.7) in the GA or AA group, hence there was no statistically differ-
ence detectable (p = 0.28). Also in the UC group there was no significant difference in the age
at diagnosis between the genotypes (GG versus GA/AA) with a median age at diagnosis of 29.0
years (q25-q75: 20.4–39.2; min-max: 3.1–79.6) within the GG genotype and 30.3 years
(q25-q75: 23.0–38.5; min-max: 5.7–74.1) within the GA or AA genotype (p = 0.53; S3 Table;
Fig 2A+2B). Next, we addressed demographic parameters and clinical phenotypes including
gender, initial or current disease location, history of surgery, history of stenosis or fistulae and
extra-intestinal manifestations in CD patients, but no significant differences between the geno-
types were detected when using a chi-squared test (Table 2).
Association with malabsorption in UC patients and vitamin D and
calcium deficiency in CD patients
We next analysed, whether PTPN22 variation might be associated with malabsorption and
vitamin deficiency in IBD patients. In the UC group, malabsorption syndrome showed a statis-
tically different distribution between the genotypes with 24 (3.37%) patients with
Fig 2. No difference in age at diagnosis in UC and CD patients carrying the A-allele in SNP rs2476601.
The graphs showmedian age at first diagnosis (bold horizontal line), values within the 25% and 75%
percentile (Box borders), and outliers (dots) in (A) UC, and (B) CD patients homozygous for the mayor (G)
allele or heterozygous/homozygous carriers of the minor (A) allele in PTPN22 SNP rs2476601.
doi:10.1371/journal.pone.0160215.g002
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Table 2. Association of PTPN22 rs2476601 SNPwith clinical parameters in CD.
Number (%) GG GA or AA p-value (chi2)
Gender distribution
Men 524 (50.68%) 69 (49.64%) 0.818
Women 510 (49.32%) 70 (50.36%)
Disease location
Initial disease location
L1 203 (21.50%) 29 (22.66%)
L2 209 (22.14%) 27 (21.09%)
L3 523 (55.40%) 69 (53.91%) 0.548
L4 9 (0.95%) 3 (2.34%)
Unknown 90 missing 11 missing
Current disease location
L1 221 (23.14%) 33 (25.78%)
L2 211 (22.09%) 28 (21.88%)
L3 514 (53.82%) 64 (50.00%) 0.449
L4 9 (0.94%) 3 (2.34%)
Unknown 79 missing 11 missing
Fistula, stenosis, surgery
Perianal ﬁstula
No 778(75.24%) 102 (73.38%) 0.634
Yes 256 (24.76%) 37 (26.62%)
Other ﬁstula
No 816 (78.92%) 119 (85.61%) 0.065
Yes 218 (21.08%) 20 (14.39%)
Anal ﬁssure
No 896 (86.65%) 126 (90.65%) 0.187
Yes 138 (13.35%) 13 (9.35%)
Abscess
No 753 (72.82%) 98 (70.50%) 0.565
Yes 281 (27.18%) 41 (29.50%)
Summary of History of ﬁstula
No 525 (50.77%) 72 (51.80%) 0.820
Yes 509 (49.23%) 67 (48.20%)
Stenosis
No 576 (55.71%) 75 (53.96%) 0.697
Yes 458 (44.29%) 64 (46.04%)
Surgery
No 498 (48.16%) 66 (47.48%) 0.956
Yes 536 (51.84%) 73 (52.52%)
Psoriasis and TBC
Psoriasis
No 923 (89.26%) 18 (12.7) 0.836
Yes 111 (10.74%) 124 (87.3)
TBC infection
No 924 (89.36%) 18 (12.7) 0.810
Yes 110 (10.64%) 124 (87.3)
Summary of Psoriasis and TBC infection
No 925 (89.46%) 18 (12.7) 0.784
Yes 109 (10.54%) 124 (87.3)
(Continued)
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Table 2. (Continued)
Number (%) GG GA or AA p-value (chi2)
Complications
Osteopenia (–porosis)
No 777 (75.15%) 114 (82.01%) 0.075
Yes 257 (24.85%) 25 (17.99%)
Deep Venous Thrombosis
No 1010 (97.68%) 135 (97.12%) 0.686
Yes 24 (2.32%) 4 (2.88%)
Pulmonary Embolism
No 1019 (98.55%) 138 (99.28%) 0.485
Yes 15 (1.45%) 1 (0.72%)
Gallstone
No 973 (94.10%) 132 (94.96%) 0.683
Yes 61 (5.90%) 7 (5.04%)
Nephrolithiasis
No 981 (94.87%) 136 (97.84%) 0.123
Yes 53 (5.13%) 3 (2.16%)
Malabsorption syndrome
No 956 (92.46%) 130 (93.53%) 0.652
Yes 78 (7.54%) 9 (6.47%)
Perforation / Peritonitis
No 989 (95.65%) 131 (94.24%) 0.455
Yes 45 (4.35%) 8 (5.76%)
Adv. Effect of Treatment
No 899 (86.94%) 122 (87.77%) 0.785
Yes 135 (13.06%) 17 (12.23%)
Summary of Complications
No 590 (57.06%) 82 (58.99%) 0.665
Yes 444 (42.94%) 57 (41.01%)
Extraintestinal manifestations
Peripheral arthritis
No 514 (49.71%) 71 (51.08%) 0.908
Yes 520 (50.29%) 68 (48.92%)
Uveitis / Iritis
No 900 (87.04%) 125 (89.93%) 0.314
Yes 134 (12.96%) 14 (10.07%)
Pyoderma gangrenosum
No 1019 (98.55%) 137 (98.56%) 0.987
Yes 15 (1.45%) 2 (1.44%)
Erythema nodosum
No 958 (92.65%) 127 (91.37%) 0.600
Yes 76 (7.35%) 12 (8.63%)
Aphtous oral ulcers
No 877 (84.82%) 124 (89.21%) 0.245
Yes 157 (15.18%) 15 (10.79%)
Ankylosing spondylitis
No 942 (91.10%) 127 (91.37%) 0.871
Yes 92 (8.90%) 12 (8.63%)
(Continued)
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malabsorption syndrome in the GG group compared to 0% in the GA or AA group (P = 0.026;
Fig 3A and S3 Table). Malabsorption is neither well defined in the Swiss IBD cohort nor in the
gastroenterological literature in general, and its occurrence in UC patients is rather uncom-
mon. Further, deficiency of vitamin K and vitamin D are associated with active intestinal
inflammation[37, 38]. Analysis of these factors revealed that CD patients carrying the A-allele
suffered less often from vitamin D and calcium deficiency (Fig 3B+3C and Table 3). In UC
patients, however, presence of the A-allele was associated with increased occurrence of vitamin
D deficiency (Fig 3B and Table 4), while for none of the other analyzed factors the distribution
was significantly different between the genotypes (Tables 3+4).
Discussion
In our study, we analyzed whether presence of SNP rs2476601 within PTPN22 is associated
with disease characteristics in patients suffering from IBD. Using the longitudinal and prospec-
tively obtained data from the SIBDC, we found that CD patients carrying the A-allele need less
often steroids and/or antibiotic treatment, while no difference was detected regarding the use
of anti-TNF antibodies. CD patients with the GA or AA genotype further suffer less often from
vitamin D and calcium deficiency. In UC patients, presence of the A-allele was associated with
enhanced use of anti-TNF medication and reduced prevalence of malabsorption syndrome,
but at the same time—and in line with more severe disease—vitamin D deficiency was more
common in those patients. In our study population, however, no significant difference could be
found between genotypes when analysing other markers of (severe) disease, such as gender,
Table 2. (Continued)
Number (%) GG GA or AA p-value (chi2)
Prim. scler. cholangitis
No 1026 (99.23%) 136 (97.84%) 0.113
Yes 8 (0.77%) 3 (2.16%)
Other
No 974 (94.20%) 133 (95.68%) 0.469
Yes 60 (5.80%) 6 (4.32%)
Summary of Extraintestinal manifestations
No 412 (39.85%) 58 (41.73%) 0.793
Yes 622 (60.15%) 81 (58.27%)
doi:10.1371/journal.pone.0160215.t002
Fig 3. Presence of SNP rs2476601 affects malabsorption, vitamin D and calcium deficiency. A:
percentage of UC patients with malabsorption syndrome. B+C: percentage of CD (left two bars) and UC
patients (right two bars) featuring (white area) or not featuring (black area) B: vitamin D deficiency, or C:
calcium deficiency.
doi:10.1371/journal.pone.0160215.g003
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initial or current disease location, surgery, history of stenosis or fistula and extra-intestinal
manifestations.
GWAS previously associated SNP rs2476601 with reduced risk for developing CD, since
this variant is less prevalent in CD patients than in the normal population. In the here pre-
sented study, we expanded this knowledge to affected IBD patients, where we found that even
in patients suffering from CD, SNP rs2476601 seems to have some protective effects: steroids
are usually used in more severe disease, and the use of antibiotics typically results from compli-
cations and/or infections, hence reduced use of these two medications indicate that the
Table 3. Association of PTPN22 rs2476601 SNPwith BMI andmicronutrient deficiency in CD patients.
Crohn’s disease patients GG GA or AA p-value (Wilcoxon)
BMI
Median (q25 –q75, Min–Max) 22.7 (20.2–25.8, 12.5–48.1) 22.3 (19.5–25.9, 15.4–37.0) 0.424
Unknown: 11 9 missing 2 missing
Hb level
Median (q25 –q75, Min–Max) 136.7 (128.2–145.8, 83–179) 138.2 (129–147, 97.5–168) 0.428
Unknown: 6 4 missing 2 missing
Vit. B12 deﬁciency
No 684 (76.68%) 88 (76.52%)
Yes 208 (23.32%) 27 (23.48%) 0.970
Unknown: 166 142 missing 24 missing
Folate deﬁciency
No 499 (64.14%) 64 (68.82%)
Yes 279 (35.86%) 29 (31.18%) 0.372
Unknown: 302 256 missing 46 missing
Anaemia
No 625 (60.68%) 89 (64.96%)
Yes 405 (39.32%) 48 (35.04%) 0.334
Unknown: 6 4 missing 2 missing
Iron def. Anaemia 17 missing
No 787 (84.26%) 106 (86.89%)
Yes 147 (15.74%) 16 (13.11%) 0.451
Unknown: 117 100 missing
Iron def. + chronic disease anemia
No 920 (98.50%) 122 (100%)
Yes 14 (1.50%) 0 (0%) 0.173
Unknown: 117 100 missing 17 missing
Calcium
No 523 (50.58%) 83 (59.71%)
Yes 511 (49.42%) 56 (40.29%) 0.043
Unknown: 0
Vitamin D
No 480 (46.42%) 78 (56.12%)
Yes 554 (53.58%) 61 (43.88%) 0.032
Unknown: 0
Folic acid
No 733 (70.89%) 101 (72.66%)
Yes 301 (29.11%) 38 (27.34%) 0.665
Unknown: 0
doi:10.1371/journal.pone.0160215.t003
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existence of the A-allele might protect from (severe and/or complicated) CD or might lead to a
milder/less complicated disease course. Nevertheless, mechanistic data directly supporting
these findings are lacking, hence our conclusion regarding the influence on disease severity
should be regarded with caution. Since vitamin D deficiency is associated with active disease
and a more severe disease course, the reduced abundance of vitamin D deficiency in CD
patients with the GA or AA genotype further supports our hypothesis that the A-allele might
be protective in CD. From basic research, it is not obvious why presence of SNP rs2476601
would result in reduced disease severity in CD. Most studies demonstrated that presence of the
Table 4. Association of PTPN22 rs2476601 SNPwith BMI andmicronutrient deficiency in UC patients.
UC / IC patients GG GA or AA p-value (Wilcoxon)
BMI
Median (q25 –q75, Min–Max) 23.2 (20.9–26.2, 14.3–45.9) 22.9 (21.0–25.9, 13.6–48.8) 0.758
Unknown: 8 6 missing 2 missing
Hb level
Median (q25 –q75, Min–Max) 136 (127.5–145.7, 70–175) 137 (127.6–147.3, 86.5–168) 0.337
Unknown: 22 20 missing 2 missing
Vit. B12 deﬁciency
No 463 (85.42%) 84 (80.00%)
Yes 79 (14.58%) 21 (20.00%) 0.159
Unknown: 208 170 missing 38 missing
Folate deﬁciency
No 328 (68.19%) 59 (62.77%) 0.305
Yes 153 (31.81%) 35 (37.23%)
Unknown: 280 231 missing 49 missing
Anaemia
No 406 (58.67%) 87 (61.70%)
Yes 286 (41.33%) 54 (38.30%) 0.504
Unknown: 22 20 missing 2 missing
Iron def. Anaemia
No 505 (83.33%) 108 (87.10%)
Yes 101 (16.67%) 16 (12.90%) 0.298
Unknown: 125 106 missing 19 missing
Iron def. + chronic disease anemia
No 581 (95.87%) 116 (93.55%)
Yes 25 (4.13%) 8 (6.45%) 0.256
Unknown: 125 106 missing 19 missing
Calcium
No 373 (52.39%) 60 (41.96%)
Yes 339 (47.61%) 83 (58.04%) 0.023
Unknown: 0
Vitamin D
No 364 (51.12%) 61 (42.66%)
Yes 348 (48.88%) 82 (57.34%) 0.065
Unknown: 0
Folic acid
No 596 (83.71%) 119 (83.22%)
Yes 116 (16.29%) 24 (16.78%) 0.885
Unknown: 0
doi:10.1371/journal.pone.0160215.t004
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A-allele results in changes in T-cell responses, ultimately promoting inflammatory T cell sub-
sets[23, 25, 39], and during innate immune reactions, presence of the A-allele has been shown
to promote inflammatory macrophages[30], also indicating an inflammation-prone pheno-
type. However, in contrast to other inflammatory disorders, in the intestine rapid clearance of
invading pathogens is crucial for homeostasis, and it might well be that the more inflammation
prone nature of the (first) immune response in A-allele carriers might result in a faster clear-
ance of infections in an early stage of the disease, preventing the development of more severe
infections needing antibiotic treatment, as well as the development of progressed chronic
inflammation.
Of special interest are the findings in the UC patient group: even though in most GWAS no
association of PTPN22 SNP rs2476601 with UC was found[11, 12], and one study in a Danish
IBD cohort even found reduced risk to develop UC upon presence of SNP rs2476601[9], our
study in contrast suggests that the A-allele might have a disease-promoting role. In contrary to
the before mentioned studies, we addressed clinical associations, i.e. how the variants influences
disease course in IBD, rather than the risk to develop the disease in a first place, which might
explain these opposed observations. In particular, we found that UC patients with the GA or
AA genotype needed anti-TNF medication more often than patients with the GG genotype.
Since anti-TNF medication is usually used in more severe, treatment refractory disease, this
might be an indication that presence of the A-allele possibly results in a more pronounced dis-
ease course in UC patients. Direct mechanistic data to support this finding are lacking, but some
data, describing how PTPN22 affects cellular pathways involved in IBD, have been published
recently[28, 29, 40] and are reviewed elsewhere[41]. There was no difference for the use of
6-mercaptopurine (6-MP), but the use of azathioprine (AZA) was significantly enhanced in UC
patients carrying the A-allele, what again indicates a promoting role for the variant. Taken
together this suggests that presence of the A-allele might have relevance not only for CD but
also for UC patients. However, presence of the A-allele was not associated with altered response
neither to the use of anti-TNF medication, nor the use of antibiotics nor steroids. This is consis-
tent with previous findings in the above-mentioned Danish cohort, where the A-allele was also
not found to be associated with changes in the response to anti-TNF treatment [9].
It might be surprising that the same genetic variant shows opposite effects on disease sever-
ity in CD and UC. The evidence pointing towards enhanced disease severity in UC is well in
line with the A-allele being associated with increased risk for other autoimmune disorders. On
the other hand, it is not surprising that the A-allele has a protective effect in CD, since GWAS
have associated this allele with reduced risk to develop CD.
From a mechanistic point of view, the opposite findings on CD and UC disease characteris-
tics might be explained by the fact that the PTPN22 variant affects T cell biology[22, 25], as
well as pro-inflammatory signalling in tissue macrophages [30]. It is clear that the role of T cell
biology is different between UC and CD, with UC classically being regarded as a Th2-mediated
disorder, while in CD Th1-signature cytokines play a dominant role[42]. Therefore, changes in
T cell biology, as induced by presence of the PTPN22 variant, likely have different effects on
UC and CD development.
Malabsorption was significantly less often found in UC patients carrying the A-allele. Mal-
absorption in IBD patients is mainly caused through the presence of severe inflammation of
the ileum and subsequent insufficient nutrient absorption as well as previous intestinal resec-
tion. In UC, the small intestine is typically not affected, however, malabsorption is known to
occur in patients with high numbers of bowel movements thus indicating more severe disease.
Micronutrition deficiency is common in IBD patients, although less prevalent in UC patients
than in CD patients[43, 44]. Since micronutrition deficiencies are associated with severe dis-
ease course[43, 45], the finding that less UC patients carrying the A-allele show malabsorption,
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somehow contradicts severe disease in those patients. However, UC patients carrying the A-
allele showed calcium deficiency more often, and no other factor associated with malabsorp-
tion was affected. Taken together this again supports the hypothesis that UC patients carrying
the A-allele might suffer from more sever disease.
CD patients with the GA or the AA genotype suffered less often from vitamin D and cal-
cium deficiencies. This is of interest, since vitamin D deficiency is known as a risk factor for
IBD, and is associated with active disease[37, 46]. Animal studies have further shown that vita-
min D and vitamin D receptor (VDR) are important regulators of immune homeostasis: vita-
min D reduces the proliferation of CD8+ cytotoxic T cells [47], and shifts the T helper cell
balance away from (pro-inflammatory) Th1 and Th17 cells towards IL-10 producing Th2 and
regulatory T cells[48, 49]. Further, vitamin D influences several pathways involved in IBD
pathogenesis, such as NOD2 signalling and autophagy[48, 50]. Therefore, a positive influence
on vitamin D levels upon presence of the A-allele might also contribute to a less severe disease
course.
A drawback of our study might be that we only addressed one single SNP, and did not take
other genetic variants in account that might be present in some of the patients. Of special inter-
est in this regard is the fact that, aside the here addressed SNP rs2476601, another variant in
the gene locus encoding PTPN22 (SNP rs33996649) has been described to affect susceptibility
for IBD. This variant results in a loss of PTPN22 phosphatase function, and has been described
to protect from the onset of UC[12]. Unfortunately the patients enrolled in the Swiss IBD
cohort have not been genotyped for SNP rs33996649, therefore analysing phenotype changes
associated with this variant was not possible.
Given the number of IBD-associated SNPs, it is likely that a significant number of patients
might be carrying not only one, but several disease-associated SNPs. Since presence of several
SNPs might have cumulative or even multiplying effects on clinical outcome, it would be of
great interest to stratify patients carrying the PTPN22 SNP rs2476601 according to the pres-
ence of other genetic variants. However, since SNP rs2476601 is rather rare, there are not
enough A-allele carriers within the Swiss IBD cohort to draw meaningful conclusions from
such analysis.
A limitation of our study might be that we did not include healthy subjects, especially since
the occurrence of SNP rs2476601 is rather low with only 0.6% in CD patients. However, in the
healthy population, the SNP is more frequent (between 1–2%), and genetic variance is rather
low in a small country such as Switzerland. The main focus of our study was to determine how
presence of SNP rs2476601 affects disease characteristics in IBD patients; hence including
healthy controls would not add significant value to achieve this aim. Further, it has already
been described thoroughly that SNP rs2476601 is associated with IBD[9, 11, 12]. For these rea-
sons, we refrained from including healthy controls in our study.
Despite these limiting factors, we can conclude that in summary, significantly fewer patients
in our cohort with the PTPN22-620W variant (GA or AA genotype) were treated with steroids
and antibiotics in CD, but more with azathioprine and anti-TNF antibodies in UC. Although
no disease-promoting association of the PTPN22 SNP rs2476601 with UC was described
before, we demonstrated, that significantly fewer UC patients carrying the variant developed
malabsorption syndrome, but vitamin D and calcium deficiency was more common. These
findings might suggest a milder disease course of CD but aggravated disease in UC in A-allele
carriers. This opposite influence of the A-allele on CD and UC disease development supports
the hypothesis that these two forms of IBD are distinct disease entities. Since PTPN22 is
involved in immune cell regulation, our findings are in line with previous findings showing
that UC and CD are distinct in their immunological signature[42]. Our findings are of interest,
since presence of the A-allele in PTPN22 SNP rs2476601 is associated with several autoimmune
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disorders, but, to the best of our knowledge, it is currently not known how the A-allele influ-
ences disease course or treatment characteristics in any of these disorders. Therefore, our study
is the first to address a clinical relevance of SNP rs2476601, and helps to better understand its
effect on disease course and treatment options in IBD patients.
Materials and Methods
Study Design
Patient data were obtained from the register of the nationwide SIBDCS, in which patients with
IBD from all regions of Switzerland have prospectively been included since 2006[51]. The
cohort study is supported by the Swiss National Science Foundation. The cohort goals and
methodology are described elsewhere[51].
We included 2028 IBD patients that were enrolled in the study at time of data acquisition
and had been previously genotyped for the CD-associated risk variant rs2476601 within the
PTPN22 gene locus. Genotyping was performed as part of an analysis of the whole Swiss IBD
cohort for all SNPs that are currently known to be associated with IBD. Since UC and IC share
several disease characteristics and indeterminate colitis is often managed the same as patients
who have UC, UC and IC patients were pooled for the analysis in order to increase sample size.
The PTPN22 polymorphism rs2476601 occurs in three possible isoforms: homozygous wild-
type (GG), heterozygous (GA), and homozygous variant (AA). The goal of this study was to
analyze whether the presence of the GA- or AA-form is associated with clinical characteristics
of IBD patients.
Clinical phenotypes of CD were classified regarding disease location, which was stratified
into 1 of 4 groups according to the Montreal classification and analyzed separately for initial
location and current location: ileal disease with or without disease limitation to the cecum (L1),
a disease limited to the colon (L2), an ileal disease with disease of the colon beyond the cecum
(L3), or disease of the upper gastrointestinal tract (L4). Patients with fistulae were classified
into four groups: perianal fistula, other type fistula (non-perianal fistula), multiple fistulae
(>1) and any type fistula. Presence of any intestinal stenosis was included in the analysis as
positive for stenosis. Location of UC was classified according to the Montreal classification into
proctitis (L1), left-sided colitis (L2), pancolitis (L3) or “location unknown”[52]. We also
included history of intestinal surgery. Gender, age at diagnosis, smoking history, and presence
of extraintestinal manifestations were taken into account. We further obtained data about cur-
rent and prior treatment with 5-aminosalicylate, antibiotics, steroids, immunosuppressants
(namely azathioprine/6-mercaptopurine), calcineurin inhibitors (tacrolimus, cyclosporine),
and anti-TNF drugs (infliximab, adalimumab, and certolizumab) at enrollment or according to
the term “ever treated with”. Anti-TNF non-response was defined as one of the following: (1)
breakthrough / loss of response, (2) primary non-response (never effective), (3) therapy stop
due to side effects / intolerance.
We further analysed whether A-allele carriers suffer from micronutrient deficiencies, such
as iron, vitamin B12, vitamin D, calcium, or folate deficiency, which might all result from
defective absorption due to severe inflammation. A further consequence of malabsorption
would be a decreased body-mass-index and decreased Hb levels. Malnutrition and micronutri-
ent deficiencies are common in IBD patients[43, 44], and are associated with more severe dis-
ease[43, 45] and longer hospitalization times[53].
Statistical Analysis
Clinical data were retrieved from the data center of the Swiss IBD Cohort Study at the Univer-
sity of Lausanne. These data and additional data obtained from a review of the patients' files
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were entered into a database (Access 2000; Microsoft Switzerland Ltd Liab. Co., Wallisellen,
Switzerland). The Statistical Package for the Social Sciences (version 21; SPSS, Chicago, IL) was
used for the statistical analysis.
Crude differences about the association of the PTPN22 variant in relation to fistulae, steno-
sis, smoking status, disease location, age at diagnosis, medications and history of intestinal
resection surgery were assessed using the Pearson's [chi]2 test or the Fisher's exact test (Fisher's
exact test used if strata comprised a sample size5). A multiple logistic regression model was
calculated to identify the associations for this gene variant. Differences about the association of
the PTPN22 variant in relation to age at diagnosis were assessed using a Wilcoxon rank-sum
test. A p-value smaller than 0.05 was considered significant.
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